A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice

201099 citationsJournal Articlegold Open Access

Authors

Gunther Spohn · Kuros Biosciences (Switzerland)

Gary T. Jennings

B Martina · Erasmus MC

Iris Keller · AO Foundation

Markus Beck · Swiss Integrative Center for Human Health

Paul Pumpens · Latvian Biomedical Research and Study Centre

Albert D. M. E. Osterhaus · Erasmus University Rotterdam

Abstract

The immunogenicity of DIII can be strongly enhanced by conjugation to virus-like particles of the bacteriophage AP205. The superior immunogenicity of the conjugate vaccine with respect to other DIII-based subunit vaccines, its anticipated favourable safety profile and low production costs highlight its potential as an efficacious and cost-effective prophylaxis against WNV.

Topics & Keywords

Mosquito-borne diseases and control Viral Infections and Vectors HIV Research and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Virology Journal

Volume 7, Issue 1, pp. 146-146

DOI: 10.1186/1743-422x-7-146

Field-Weighted Citation Impact: 7.29